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ReviewEndoplasmic reticulum stress, degeneration of
pancreatic islet b-cells, and therapeutic
modulation of the unfolded protein response in
diabetesRajarshi Ghosh 1,2,3,4, Kevin Colon-Negron 1,2,3,4, Feroz R. Papa 1,2,3,4,*ABSTRACT
Background: Myriad challenges to the proper folding and structural maturation of secretory pathway client proteins in the endoplasmic re-
ticulum (ER)d a condition referred to as “ER stress”d activate intracellular signaling pathways termed the unfolded protein response (UPR).
Scope of review: Through executing transcriptional and translational programs the UPR restores homeostasis in those cells experiencing
manageable levels of ER stress. But the UPR also actively triggers cell degeneration and apoptosis in those cells that are encountering ER stress
levels that exceed irremediable thresholds. Thus, UPR outputs are “double-edged”. In pancreatic islet b-cells, numerous genetic mutations
affecting the balance between these opposing UPR functions cause diabetes mellitus in both rodents and humans, amply demonstrating the
principle that the UPR is critical for the proper functioning and survival of the cell.
Major conclusions: Specifically, we have found that the UPR master regulator IRE1a kinase/endoribonuclease (RNase) triggers apoptosis, b-
cell degeneration, and diabetes, when ER stress reaches critical levels. Based on these mechanistic findings, we find that novel small molecule
compounds that inhibit IRE1a during such “terminal” UPR signaling can spare ER stressed b-cells from death, perhaps affording future op-
portunities to test new drug candidates for disease modification in patients suffering from diabetes.
 2019 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords Endoplasmic reticulum stress; Unfolded protein response; Diabetes mellitus; Kinase; Endoribonuclease; Apoptosis; Small molecule
kinase inhibitor1. INTRODUCTION
One third of all eukaryotic proteins are secreted to the cell exterior or
inserted into membranes. Biogenesis of these secretory pathway client
proteins begins in the endoplasmic reticulum (ER) through the concerted
actions of an ER-resident protein-folding machinery comprising chap-
erones, glycosylating enzymes, and oxido-reductases [1]. But if demand
on the ER protein-folding machinery exceeds its capacity, unfolded client
secretory proteins start to accumulate within the organelle. Such “ER
stress” can occur from simply having to make too much of any given
secretory protein; thus, professional secretory cellsd such as insulin-
producing pancreatic islet b-cellsd are especially at risk because they
typically work at the limits of their secretory capability. Under ER stress,
secretory proteins accumulate in unfolded/immature forms to activate
intracellular signaling pathways called the unfolded protein response
(UPR). Through adaptive (‘A’-UPR) outputs, transcription of genes
encoding ER-resident protein-folding enzymes and ER-associated
degradation (ERAD) components is augmented while translation of
secretory proteins is temporarily reduced [2e7].1Department of Medicine, University of California, San Francisco San Francisco, CA,
Francisco, CA, 94143-2520, USA 3Lung Biology Center, University of California, San F
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S60 MOLECULAR METABOLISM 27 (2019) S60eS68  2019 Published by Elsevier GmbH. This isBut if the cell still continues to experience ER stress at levels that
cannot be remedied, the UPR instead maladaptively “overshoots”,
causing cell cycle arrest, dedifferentiation, senescence, and sterile
inflammation, ultimately culminating in apoptosis; the spectrum of
these destructive outputs is termed the terminal UPR (‘T’-UPR) [3].
Apoptosis of irremediably stressed cells is an extreme, yet definitive,
quality control strategy that protects multicellular organisms from
exposure to immature and damaged secretory proteins. At the cost of
losing some cells, multicellular organisms may benefit temporarily
from T-UPR-induced apoptosis. However, many human cell degener-
ative diseases occur when too many cells die through this process and
are not replaced by proliferation. For instance, diabetes mellitus de-
velops once the functioning mass of an individual’s insulin-producing
b-cells is reduced to below a critical threshold; thus, this may be an
archetype of the overall T-UPR induced concept for other diseases.
Despite having evolved a large and robust ER, pancreatic b-cells have
an innate fragility and are susceptible to secretory pathway overload
because they are mandated to synthesize and secrete insulin in the
large and requisite amounts needed to buffer blood glucose fluxes [8]94143-2520, USA 2Diabetes Center, University of California, San Francisco San
rancisco San Francisco, CA, 94143-2520, USA 4Quantitative Biosciences Institute,
14 9656. E-mail: frpapa@medicine.ucsf.edu (F.R. Papa).
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d more than 1 million molecules of insulin produced/b-cell/minute
(i.e., working near limits of their protein synthetic capacity). Under
elevated insulin demand, protein folding and structural maturation in
the b-cell ER becomes exhausted as the homeostatic ‘A’-UPR morphs
into a destructive ‘T’-UPR [9,10].
As detailed later in this review, rare gene mutations in both b-cell
secretory cargo (i.e., proinsulin variants), and in UPR gene products
cause UPR dysregulation and b-cell degeneration/apoptosis, leading to
diabetes in rodent models (and in some human diabetes syndromes);
furthermore, peripheral insulin resistance has also been linked to
premature b-cell death and diabetes through UPR dysregulation
[8,11e14]. For instance, type 2 diabetes (T2D) occurs under obese/
overweight conditions that force b-cells to overproduce insulin in order
to counter peripheral insulin resistance. Chronic UPR activation is
evident in islets of patients with T2D and those at risk before overt
disease appears [15]. Similarly, we, and others, have found that ‘A’- to
‘T’-UPR conversions occur in murine models of type 1 diabetes (T1D),
a disease initiated by autoimmune T-cell-mediated attack against b-
cells [13,16,17]. Specifically, stereotypic ‘A’- to ‘T’-UPR conversions
occur in b-cells of the T1D model, non-obese diabetic (NOD) mouse,
after innate/adaptive immune infiltration (insulitis) starts, but before
diabetes ensues [17]. While ‘A’-UPR homeostatic outputs wane, ‘T’-
UPRedestructive outcomes in the immune-targeted b-cells cause b-
cell functional mass to decline, further increasing stress in remaining
b-cells [13].
Thus in T1D, the b-cell may become complicit in its own demise (i.e.,
through suicided not just homicide) under unrelenting stress caused
by immune attack [18]. A unifying theory of b-cell failure posits that (as
in the rare, monogenetic syndromes) UPR dysregulation contributes to
b-cell failure in the etiology and pathogenesis of the common (poly-
genic) syndromes of diabetes (types 1 and 2; Figure 1). However, our
knowledge of these events and translation of these experimental
studies into human diabetes contexts is still very much in the pre-
liminary stages. In this review we will highlight salient features of the
early secretory pathway and the general case for UPR involvement in
b-cell failure, as well as focus attention on an emerging kinase target
for small molecule modulation of the UPR as potential therapies for b-
cell sparing during ER stress.Figure 1: ‘A’- to ‘T’-UPR conversions may promote b-cell death in diabetes. During
unmitigated, terminal UPR signaling drives destructive outputs culminating in b-cell apopt
cycles promoting diabetes. These principles may be a unifying feature in monogenetic and
loss of function of critical UPR components (e.g., PERK) dysregulates the pathway leadin
expression in the MIDY syndrome caused by the (C96Y) Akita variant. In T1D, islet immune
overwork in T2D. It is conceivable that similar events that occur in the murine models d
MOLECULAR METABOLISM 27 (2019) S60eS68  2019 Published by Elsevier GmbH. This is an open acc
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PROTEIN RESPONSE (UPR) SIGNALING
In all eukaryotic cells, soluble and transmembrane proteins destined
for many intra-cellular organelles, the plasma membrane, or the
extracellular space, initially fold to their native shapes and structurally
mature within the ER [19,20]. These protein-folding and maturation
reactions are catalyzed by ER-resident molecular chaperones, glyco-
sylating enzymes, oxido-reductases, and other protein-modifying ac-
tivities. Molecular chaperones hydrolyze ATP to sequentially bind and
release nascent secretory proteins, thereby reducing off-pathway
aggregation during folding of secretory protein clients. Glycosylating
enzymes add and trim sugar moieties from client proteins. ER oxido-
reductases generate and sustain an oxidizing environment within the
ER that facilitates formation of disulfide bonds in maturing client
proteins [21,22]. Overall, these early secretory pathway processes are
energy-intensive and enzymatically mediated d the ER-resident ac-
tivities that regulate these processes constitute a “protein-folding
machinery” that maximizes the probability that secretory pathway
client proteins, such as proinsulin, become properly folded, modified,
and sometimes assembled into multi-protein complexes before they
exit the ER towards the Golgi and distal organelles.
It is however the case that a substantial fraction of secretory proteins
normally fails to fold and mature properly within the ER. Such proteins
are extracted from the ER to the cytosol, (poly)ubiquitylated, and
degraded by the 26S proteasome (a process referred to as ER-
associated degradation or ERAD) [5,23,24]. Misfolded secretory pro-
teins are also removed through autophagy [25,26]. These stringent
quality control processes notwithstanding, cells frequently encounter
acute and/or chronic environmental challenges during which protein-
folding demand in the ER overwhelms protein-folding capacity,
causing these protein quality control systems to break down. Myriad
challenges, both physiological and pathological, can provoke such ER
stress. For instance, ischemia depletes cellular energy stores due to
nutrient and oxygen deprivation, which in turn compromises the
energy-intensive processes of protein modification and folding in the
ER [27]. While overproduction of secretory proteins can generate ER
stress, this is especially true for mutant forms of secretory proteins thatER stress, adaptive UPR outputs maintain cellular homeostasis. If ER stress remains
osis. Declining b-cell mass elevates workload/ER stress in remaining b-cells in vicious
polygenetic forms of diabetes (both rare and common). In various UPR gene mutations,
g to infantile diabetes. Gain-of-function proteotoxicity accompanies mutant proinsulin
cell infiltration elevates ER stress in b-cells. Peripheral insulin resistance elevates b-cell
rive b-cell degeneration in human T1D and T2D.
ess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). S61
Revieware particularly difficult to fold d see the example of “Akita” insulin
later.
Cells are alerted to the presence of unfolded proteins within the ER by
three ER trans-membrane signaling proteins named IRE1a, PERK, and
ATF6 (Figure 2). These “first responders” become activated through
direct and/or indirect binding of unfolded proteins within the ER [28e
32]. Combinatorial signals from IRE1a, PERK, and ATF6 initially trigger
transcriptional programs that upregulate genes encoding many of the
aforementioned ER-resident protein-folding machines. Specifically,
ATF6 is a latent transcription factor that gets cleaved in the plane of ER
membrane during ER stress and translocates to the nucleus to upre-
gulate numerous genes that encode ER protein folding activities. IRE1a
and PERK are both serine/threonine kinases whose outputs also lead to
production of specific transcription factorsd ATF4 in the case of PERK
and XBP1 in the case of IRE1a that trans-activate genes necessary for
augmenting ER secretory function. Thus, by increasing the comple-
ment of ER protein-folding and quality control machinery [2], the UPR
increases the cell’s capacity to maintain healthy protein secretion in
the face of manageable levels of ER stress. Through PERK activation
the UPR also imposes a transient translational block (at the level of
translation initiation) during ER stress, thereby concentrating available
resources to aid the maturation of existing proteins before new ones
arrive into the ER. If these adaptive UPR outputs are successful, the
decline in levels of unfolded proteins causes UPR signaling to wane as
homeostasis is restored
However, if ER stress still remains high and/or chronic despite these
attempts, signal integration from these three UPR sensor/effectors
causes the pathway to switch its output from promoting adaptation to
instead promoting cell destruction, ultimately culminating in apoptosis
(Figure 2). Cells also appear to transition under high ER stress through
intermediate dysfunctional or de-differentiated states beforeFigure 2: The three first responders of the UPR are diagrammed. Upon activation under ER
cell to either adapt or commit apoptosis.
S62 MOLECULAR METABOLISM 27 (2019) S60eS68  2019 Published by Elsevier GmbH. This iscommitting to apoptosis. Apoptosis during irremediable ER stress may
perhaps be the most stringent and definitive strategy for exerting
protein quality control since culling highly stressed cells will ensure
that they will not produce potentially dysfunctional secretory products.
As proteins of the secretory pathway include cell surface receptors and
polypeptide hormones, which mediate crucial signaling roles, the cell
needs to ensure that these protein products are pristine and will not
tolerate faulty versions. Thus, at the cost of culling irreversibly-
stressed cells, multi-cellular organisms may thus benefit from
employing UPR-induced apoptosis as a stringent and definitive protein
quality control mechanism. However, if UPR-induced apoptosis be-
comes too vigorous and unchecked, organisms will suffer organ failure
due to an insufficient mass of functioning cells. This principle is on
vivid display in many different examples of pancreatic islet b-cell
degeneration during ER stress-induced development of diabetes
mellitus.
3. IRREMEDIABLE ER STRESS PROMOTES APOPTOSIS OF b-
CELLS TO CAUSE DIABETES
b-cells contain highly developed ERs since their raison d’être is to
produce insulin continuously during their lives [8]. Insulin biogenesis
requires a complex series of molecular biosynthetic events that initiate
in the ER [33]. After translation, insulin precursor, pre-proinsulin, is
translocated into the ER lumen of b-cells, where its signal sequence is
removed, generating proinsulin. ER-resident oxido-reductases catalyze
formation of three intramolecular disulfides in proinsulin to help it fold
to its native shape. This oxidative folding event is critical for proper
structural maturation and subsequent trafficking of proinsulin to the
Golgi. In the “Akita” mouse mutant, which expresses the proinsulin
variant gene, Ins2 (C96Y), an unpaired cysteine leads to futile cycling ofstress, three sensors, IRE1a, PERK, and ATF6 send intracellular signals that allow the
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the oxidative folding process; Akita insulin is therefore arrested by the
protein quality control system in the b-cell ER where it acts as a
continuous irritant to hyper-activate the UPR [34e37]. Diabetes in the
Akita mouse is not directly caused by reduction of mature insulin levels
from the C96Y mutation. Instead, Akita insulin causes a toxic “gain-of-
function” phenotype, leading to diabetes early in life; hence it is
classified as a ‘MIDY’ syndrome d “mutant insulin-gene induced
diabetes of youth” [36]. By accumulating in the ER as a
conformationally-altered immature species that also generates reac-
tive oxygen species (ROS) due to futile oxidative folding, Akita insulin
acts as a “proteotoxin” that chronically activates the UPR [34].
Continuous UPR activation exhausts homeostatic ‘A’-UPR outputs,
causing b-cells to enter the ‘T’-UPR-driven apoptotic pathway and
leading to early diabetes in the mice [38e40]. Interestingly, rare
diabetes-causing Akita-like insulin mutations have also been
described in humans [41].
Loss-of-function mutations in the UPR also have deleterious effects in
b-cells. In one of the more interesting examples, homozygous deletion
in mice of the PERK gene encoding the UPR sensor Perk d an ER
transmembrane kinase that when activated by ER unfolded proteins
phosphorylates the eIF-2a translation initiation factor on the Ser51
residue to temporarily shut off translationd causes massive and rapid
b-cell apoptosis leading to early diabetes [42,43]. Without Perk, b-
cells cannot attenuate translation to match ER protein folding capacity,
and thereby suffer deposition of ER unfolded proteins, leading to
apoptosis [42]. Furthermore, as will be detailed below, the Perk /
genotype causes compensatory hyper-activation of the IRE1a arm, to
drive the T-UPR in professional secretory cells. A rare human diabetic
syndrome caused by PERK gene mutations (called Wolcott-Rallison
syndrome) is a phenocopy of the mouse knockout. Further, a homo-
zygous genetic knock-in of an unphosphorylatable eIF-2a (Ser51Ala)
variant (the substrate of Perk) develops a severe neonatal wasting
syndrome [44,45], and an insulin-resistant T2D-like syndrome in the
heterozygote [45]. Finally, another diabetic syndrome follows homo-
zygous loss of p58IPK [46e48], a co-chaperone needed to inhibit Perk.
In the absence of p58IPK, a continued translational block through Perk
signals a frustrated UPR cycle, leading to UPR signaling dysregulation.
Together, these experimental genetic syndromes are rare textbook
examples of ER stress deterministically causing b-cell death leading to
diabetes. But extending these concepts into human pathophysiology,
we may be able to learn whether common human diabetes syndromes,
such as types 1 and 2 diabetes (and gestational diabetes) proceed, at
least in part, from similar mechanisms. For example, T2D is a het-
erogeneous syndrome initiating with peripheral insulin resistance,
leading eventually to b-cell failure and death. Measuring ER stress in
b-cells of living humans is currently not feasible, as the pancreatic islet
b-cell mass and insulin secretory function during life cannot be studied
simultaneously. However, pancreatic autopsy series from T2D patients
show a reduction in b-cell mass [49], with relics of activated UPR
apoptotic markers. In addition, human type 2 diabetic islets contain
protein aggregates in the form of amyloid [50]. Islet amyloid is
composed of a 37-residue amyloidogenic polypeptide called islet
amyloid polypeptide (IAPP). IAPP spontaneously forms ER membrane-
damaging sheets of amyloid [51]. Therefore, IAPP could be another ER
stress link promoting b-cell death. IAPP-mediated b-cell death likely
induces ER stress through activation of the pro-apoptotic transcription
factor Chop, and Chop has been reported to be detected in islets of
human diabetics at the time of autopsy [15].
These studies inform a unified model for the development of T2D in
humans. In obese states, an acquired state of peripheral insulin
resistance causes b-cells to overwork by overproducing insulin. ThisMOLECULAR METABOLISM 27 (2019) S60eS68  2019 Published by Elsevier GmbH. This is an open acc
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voking the UPR whose outputs initially counter the stress. Over time, in
the absence of relief from the stress signal, b-cells may start to die
through UPR-mediated apoptosis. Once b-cell death commences, the
remaining b-cells will become even more overworked as they attempt
to make up for the insulin deficit, therefore experiencing further ER
stress. This b-cell “burn out” may become a vicious cycle, until
apoptosis of sufficient numbers of b-cells locks in the T2D state
[52,53].
These aforementioned mechanisms may also be operative in type 1
diabetes (T1D), a disease that initiates from autoimmune attack by T-
cells against b-cells. In addition, during gestation, increasing insulin
requirements require an approximate doubling of the b-cell mass in
humans, which we propose may expose the b-cells of pregnant
mothers to increased ER stress. In some individuals (perhaps those
who are already at risk for T2D), this could increase risk for gestational
diabetes (GDM) [54]. Indeed it is well appreciated that GDM, which
often resolves after pregnancy, puts affected mothers at risk for T2D
later in life, perhaps by reducing b-cell mass.
4. ER KINASE/RNASE IRE1a CONTROLS ENTRY INTO THE
T-UPR
How does the UPR promote binary cell fate outcomes? We found that
IRE1a d a bifunctional kinase/endoribonuclease (RNase) d is a
critical UPR life-death switch that employs its kinase auto-
phosphorylation levels as a “rheostat” to determine cell fate [55,56].
Remediable ER stress causes low-level kinase auto-phosphorylation
and dimerization that restricts IRE1a0s RNase activity to a single
adaptive task: excising an intron in XBP1 mRNA; re-ligation of spliced
XBP1 mRNA shifts its open reading frame, and its translation produces
the homeostatic transcription factor XBP1s (s ¼ spliced) [57,58],
which upregulates genes encoding ER protein-folding and quality
control components [59]. Sustained, high-level kinase autophosphor-
ylation, however, causes higher-order IRE1a oligomerization. Under
these conditions, IRE1a0s RNase relaxes its specificity and degrades
hundreds of mRNAs at the ER membrane that encode co-
translationally translocated secretory proteins [55,56,60]. Depletion
of cargo-encoding transcripts may initially be protective because this
event reduces ER protein-folding burden; but eventually the wholescale
endonucleolytic mRNA decay depletes transcripts encoding the very
structural and enzymatic components of the ER protein-folding ma-
chinery itself d i.e., ER-resident molecular chaperones, oxido-
reductases, and glycosylating enzymes. Consequently, ER protein-
folding function actively deteriorates. Thus, hyperactive IRE1a RNase
induces a T-UPR that eclipses ‘A’-UPR XBP1s outputs over time,
causing loss of differentiated b-cell identity (e.g., depletion of insulin
mRNAs), sterile inflammation, and apoptosis (Figure 3).
Furthermore, hyperactivated IRE1a RNase may promote multiple,
interlinked, downstream destructive outcomes specific to the b-cell
during high/chronic ER stress through this regulated endonucleolytic
decay of RNAseFigure 4. For instance, as wholescale mRNA decay
proceeds, loss of differentiated cell identity ensues (decreases in in-
sulin levels, proinsulin-modifying prohormone PC1/3, PC2 con-
vertases, etc.). Other ER-localized mRNAs encoding enzymatic factors
that dispose of reactive oxygen species (ROS) such as PRDX4 also
decline under IRE1a hyperactivation, perhaps causing oxidative stress.
Also, hyperactive IRE1a RNase d in competition with DICER d
causes decay of select micro RNAs (miRs) at the pre-miR level. Notably
repressive miR-17 targets the T-UPR mediator, TXNIP mRNA (a
naturally short-lived mRNA with two 30UTR miR-17 seed sequences).ess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). S63
ReviewDepletion of miR-17 causes rapid and robust increases in pro-oxidant
TXNIP protein, which then activates the NLRP3 inflammasome, leading
to pro-caspase 1 cleavage and IL-1b maturation/secretion in islets.
Therefore, genetic removal of Txnip is b-cell sparing in the Akita
mouse, [17,39]. Finally, miR-17 depletion also derepresses p21
expression, cyclin-dependent kinase inhibitor 1, through a post-
transcriptional mechanism similar to that of TXNIP d through two
miR-17 seed sequences in its 30UTR (Figure 4).
5. ‘KIRAS’ RESET ENDOGENOUS IRE1a0S EXECUTION POINT TO
SEPARATE THE A-UPR FROM THE T-UPR
Through mechanistic and chemical-biology studies, we learned that
the IRE1a-induced A-UPR could be entirely uncoupled from its T-UPR
by enforcing intermediate activation states (sufficient for splicing XBP1
mRNA, but insufficient for causing endonucleolytic decay) with select
small molecule kinase inhibitors. IRE1a0s RNase activation is normallyFigure 3: IRE1a acts as a homeostatic-apoptotic switch in response to ER stress. (A) Hom
(B).
S64 MOLECULAR METABOLISM 27 (2019) S60eS68  2019 Published by Elsevier GmbH. This isdependent on kinase autophosphorylation [61], but we discovered that
an allosteric relationship between these two domains exists, which
allows nucleotides (ADP and ATP) that stabilize an active ATP-binding
site conformation (called type I) to directly activate the RNase, while
bypassing autophosphorylation [62e64].
Based on this knowledge, we hypothesized that a different class of
kinase inhibitors (called type II) should stabilize an inactive ATP-binding
site conformation of endogenous IRE1a and inhibit its RNase activity by
breaking high-order oligomerization, to consequently reduce both ki-
nase and RNase activities in tandem and thereby also enforce an in-
termediate activation state. We predicted that these “type II” kinase
inhibitors should stabilize the inactive ATP-binding site conformation of
IRE1a by stabilizing its Helix-aC-out conformation. This should cause
back-to-back clashes between IRE1a protomers, shutting down RNase
activity [65]. We named these small molecules ‘KIRA’sd the acronym
stands for kinase-inhibiting RNase-attenuators d and developed
robust biochemical assays to discover them [66].eostatic XBP1 splicing progresses to apoptotic mRNA decay if ER stress is unresolved,
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Through IRE1a RNase hyperactivationd and ER-localized mRNA and miR decayd ER stress can secondarily morph to cause oxidative stress (loss of PRDX4), loss of
differentiated cell identity (decreases in insulin mRNA and protein), inflammation (TXNIP induction), proliferation blocks, and pyroptotic/apoptotic cell death. See text for details.One early-stage KIRA, KIRA6, attenuates endogenous IRE1a in vivo, to
generally promote cell survival under ER stress in diverse models of
premature cell degeneration. For example, provided intravitreally, KIRA6
preserved photoreceptor functional viability in rat models of ER stress-
induced retinal degeneration, specifically in a model that expresses
P23H rhodopsin (a folding mutant), which causes autosomal dominant
retinitis pigmentosa [56]. Systemically, KIRA6 preserved b-cells,
increased insulin content, and reduced hyperglycemia in Akita mice
(mimicking effects of TXNIP gene deletion) [56]. Biochemical, cellular,
and in vivo data showed that a wide “therapeutic window” exists be-
tween the ‘A’- and ‘T’-UPR because endonucleolytic decay of extra-XBP1
target mRNAs such as the mRNAs encoding secretory target cargo, i.e.,
proinsulin (Ins1 or Ins2) can be quenched with lower KIRA6 concen-
trations (wnM IC50) than those needed to inhibit XBP1 mRNA cleavage
(mM IC50), owing to the fact that XBP1 mRNA is a much more efficient
substrate for IRE1a RNAse than the hundreds of other ER-localized
mRNA substrates. In other words, because lower-order species suffice
for XBP1 mRNA splicing, sub-complete IRE1a inhibition with KIRAs
selectively attenuates the T-UPR while preserving the A-UPRd with an
approximate three log10 IC50 difference separating the two outcomes.
In general, rheostatic control over A-versus T-UPR IRE1a outputs
proceeds through changes in IRE1a0s homo-oligomerization levels.
However, it has also been learned that other proteins also bind IRE1a
at the ER membrane to regulate its oligomeric state and outputs.
Various factors in other signaling pathways interact with IRE1a,
including protein-tyrosine phosphatase 1B, BAX inhibitor-1, ASK1,
RACK1, and nonmuscle myosin IIB, and tune IRE1a-outputs to affect
cell fate [67e71]. For example, the ABL-family of tyrosine kinases,
consisting of two paralogs, c-Abl and Arg [72] are also integral com-
ponents of this “UPRosome” that drives IRE1a hyperactivity at the ER.
While oncogenic BCR-Abl is the intended target of Gleevec (imatinib)
for CML, c-Abl and Arg kinases are also inhibited by this drug. Based
on successful efficacy in the NOD using Gleevec, repurposed GleevecMOLECULAR METABOLISM 27 (2019) S60eS68  2019 Published by Elsevier GmbH. This is an open acc
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human patients. However, in spite of imatinib’s efficacy in the NOD,
little was known about the relative contributions of the efficacy of this
drug on the autoimmune system versus b-cells themselves. c-Abl
kinase is induced and activated during ER stress in b-cells of NOD
mice after immune infiltration [17]. c-Abl activation relocalizes it from
the cytosol to the ER membrane to rheostatically hyperactivate IRE1a,
causing T-UPR induction and b-cell apoptosis. Imatinib reverses T-UPR
endpoints by sequestering c-Abl in the cytosol and preventing it from
binding IRE1a. Thus, FDA-approved tyrosine kinase inhibitors (TKIs)
may be repurposed to truncate the T-UPR based on rationally under-
standing their underlying mechanism of action.
A significant advance in the UPR field to directly target IRE1a occurred
with the development of a highly potent (sub-nanomolar) kinase in-
hibitor of IRE1a called compound 18 by Amgen [73]. This molecule
came out of a medicinal chemistry analoging campaign to optimize
Tie2 kinase inhibitors, but unexpectedly produced a near mono-
selective inhibitor of IRE1a. Compound 18 was further tested for its
ability to reduce survival of multiple cancer cell lines by Amgen (and
abandoned when it could not). Using an XBP1 RNA mini-substrate [65]
we confirmed that resynthesized compound 18 has all the properties of
a KIRA (hence renamed KIRA8). KIRA8 breaks IRE1a oligomerization
in vitro (Figure 5), and is highly selective against a panel of >300
kinases, including Abl (demonstrating even negligible activity against
IRE1a0s closely-related gut-expressed paralog, IRE1b) [17]Favorable
pharmacokinetic properties of KIRA8 guided daily intraperitoneal (i.p.)
dosing in pre-diabetic NODs, which within one showed decreased
TXNIP mRNA, and rescued proinsulin- and (ER chaperone) BiP-
encoding mRNAs in islets. By 4-weeks, first phase insulin responses
to an i.p. glucose load were preserved in the KIRA8 group, concomitant
with 3-fold-enhanced insulin-staining mass in pancreata. Finally, even
after overt diabetes is manifested, KIRA8 led to >90% diabetes
reversal within three weeks [17]ess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). S65
Figure 5: KIRA8 dose-dependently breaks IRE1a homo-oligomers and allosterically reduces RNAse hyperactivation. Because lower-order species suffice for adaptive
XBP1 mRNA splicing, sub-complete IRE1a inhibition with KIRAs selectively attenuates the T-UPR under high/chronic ER stress.
ReviewIn toto, the aforementioned positive efficacy results in the NOD may
therefore offer a translational opportunity in humans to study and
understand the mechanistic and physiological consequences of
modulating the ABL-IRE1a axisd from either the Abl (with TKIs such
as imatinib or nilotinib) or the IRE1a end (with evolving KIRA mole-
cules) d for healthy secretion. For instance, we predict that either
imatinib or KIRA8 will cause in human b-cells, either ex-vivo or
transplanted into immune-deficient mice: (1) blunting of human insulin
mRNA endonucleolytic decay; (2) stabilization of IRE1a0s RNase sub-
strate, (pre)miR-17, (3) consequently attenuate TXNIP, the NLRP3
inflammasome, and IL-1b; and (4) enhance proinsulin to insulin pro-
cessing (with increased human C-peptide detectable) as pro-hormone
convertases and ER-resident chaperones are preserved, thereby
increasing GSIS. Because of these intermediary outcomes, (5) we may
expect that as with murine b-cells the functioning mass of human b-
cells should be preserved. Finally, we predict that these b-cell-sparing
effects should be generald i.e., without regard to the upstream stress
that initiates disease d and extend to obesity-related diabetes (in
addition to autoimmune-induced diabetes and MIDY models).
From a development standpoint, the next challenges facing the
pharmaceutical industry in advancing KIRAs for human testing is to
improve their drug-likeness. At the time of the writing of this review,
current KIRAs lack oral bioavailability and are poorly soluble (both li-
abilities should be straightforward to correct by medicinal chemistry
analoging efforts). Further testing of KIRA candidates in numerous
in vivo murine diabetes models and in human islets reconstituted into
immune-deficient mice for dose optimization should further inform
pharmacokinetic/pharmacodynamic (A-vs. T-UPR markers) and relate
these PK/PD studies back to chronic efficacy (durability) studies as was
done for imatinib. Furthermore, while the accumulating experience
with in vivo use of KIRA8 has not shown adverse effects in rodents to
date, de-risking this class of inhibitors will require formal chronic
toxicity studies with dose-escalation in animals d especially given
that KIRAs monomerize IRE1a, it will be necessary to define the di-
mensions of an in vivo therapeutic window. Given the evolving interest
in the pharmaceutical industry for drugging the UPR through IRE1a it is
conceivable that clinical candidates for testing KIRAs for a systemic
UPR-driven cell-degenerative indication (not necessarily confined to
diabetes) in humans may be available for an investigational new drug
application (IND) to the United States Food and Drug Administration
(FDA) in the next few years.S66 MOLECULAR METABOLISM 27 (2019) S60eS68  2019 Published by Elsevier GmbH. This isIn conclusion, the long path of basic discovery and study of an intra-
cellular stress signaling pathway d the UPR d has led to potential
targets, understanding of a mechanism of action and mode of inter-
vention, and new chemical development through which the goal of b-
cell sparing in diabetes may be tested in the future. We predict that the
next few years will provide interesting insights and advances into these
topics.FUNDING
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